Although she never received any medical or surgical treatment for the deadly
cancer invading her
lungs, six weeks after starting psychosynthesis, her
tumors began to
shrink.
An anti-PD-1 antibody developed by Bristol - Myers Squibb generates excitement with results from a phase I trial showing that, among 236 patients with various types of
cancer, the treatment
shrank tumors in 28 percent of melanoma patients, 30 percent of patients with kidney
cancer, and 18 percent of patients with advanced non-small cell
lung cancer.